ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual JMP Securities Research Conference
WALTHAM, Mass.--(BUSINESS WIRE)--May 12, 2008--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the 7th Annual JMP Securities Research Conference will be webcast live. The presentation is scheduled to begin at 8:00 a.m. PDT on May 19, 2008, and will be given at The Ritz-Carlton, San Francisco, CA. The presentation will provide an update on ImmunoGen.
The webcast can be accessed through the "Investor Information" section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until May 26, 2008.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - IMGN901 and IMGN242. Three TAP compounds are in clinical testing through ImmunoGen's collaborations with other companies - trastuzumab-DM1 (T-DM1), in development by Genentech, and AVE9633 and SAR3419, in development by sanofi-aventis. Additionally, the naked antibody compound, AVE1642, is in clinical testing through the Company's collaboration with sanofi-aventis. Multiple compounds are in research/preclinical development through ImmunoGen's collaborations and internal programs.
CONTACT:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
